Tagged with HE

Switzerland In the age of AI-fuelled promises and digital transformation, SOPHiA GENETICS stands apart, not by chasing trends but by quietly reshaping how healthcare systems use data to deliver more precise, equitable, and timely care. From enabling cloud-native genomics in hospitals worldwide to advancing decentralised liquid biopsy, the company is building…

Denmark Helene Probst, Health Director, Danish Regions, outlines Denmark’s healthcare reform as a major shift from hospital-centric care to a primary care-focused system, driven by workforce shortages and an ageing population. Key changes include redistributing responsibilities to regions, creating health councils, and redefining the GP role to better serve local and…

Global As neuroscience reclaims a place at the top table of pharmaceutical innovation, Bristol Myers Squibb (BMS) is quietly reshaping its presence in the field. Spearheaded by its Neuroscience Thematic Research Center, the company is pursuing a dual mandate: to slow the progression of diseases like Alzheimer’s while also addressing their…

Hong Kong With Hong Kong now host to a growing volume of public and private entities specializing in cell and gene therapy development, some market insiders spy great opportunities for the city, with its unique background context and characteristics, to play a role shaping the next wave of biomedicine discovery.   Dr…

Hong Kong At first glance, tiny and crowded Hong Kong may not look like an obvious destination for developing next-generation gene therapies, for all its financial firepower and international complexion. Delve deeper, however, and its distinctive and differentiated offering becomes ever more apparent.    “While Hong Kong’s biomedical ecosystem certainly still lags…

Hong Kong In summer 2023, Hong Kong entered the next frontier of cancer care with the launch of its first hospital-based CAR-T clinical trial. Developed entirely within city limits by a team of clinicians and scientists at the Chinese University of Hong Kong (CUHK), Prince of Wales Hospital, and the Hong Kong…

Hong Kong Hong Kong has a burgeoning status within Greater China as an advanced therapy hub. The Special Administrative Region boasts clinical trial expertise, internationally aligned regulation, a lack of price caps, and the recently minted ability to produce cell and gene therapies within the city. This means that, today, more new…

Hong Kong Hong Kong’s unique history as a former British governate and current special status under the ‘one country, two systems’ administrative framework, endow it with many underlying advantages as a ‘talent magnet.’ From a professional standpoint, the city’s international connectivity, financial architecture, and efficient infrastructure already render it an appealing location…

Switzerland In a health and wellness landscape crowded with disputable claims and flash-in-thepan trends, A.Vogel stands out for its quiet consistency and scientific conviction. Over the past five years, the Swiss-based natural health company has doubled down on quality, transparency, and long-term vision; from scaling up GMP-certified production and running clinical…

Spain Dr Arcadi Navarro is a leading figure in modern Alzheimer’s research, heading efforts at the Pasqual Maragall Foundation in Barcelona and its university partners. His work spans genomics, bioinformatics, neurotropic viruses, and personalised brain organoids. Under his leadership, the foundation has doubled its research capacity and become a key player…

Switzerland Marking 160 years of uninterrupted evolution, Max Zeller stands at the intersection of tradition and modernity in plant-based healthcare. CEO Georg Boonen reflects on the company’s continued role in shaping evidence-based phytotherapy, from pioneering prescription-grade herbal medicines in Switzerland to launching the Zeller Plus line of preventive supplements. With a…

Global Lenny Shallcross, Executive Director of the World Dementia Council, reflects on the evolving global response to Alzheimer’s disease and dementia; from the slow but significant rollout of disease-modifying treatments to the critical importance of knowledge-sharing between health systems. Shallcross discusses why this moment, though complex and incremental, represents a turning…